News
HGP – Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues
Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide
- Walgreens becomes first retail pharmacy to offer access to AUVI-Q auto-injectors at no cost for commercially insured patients who are eligible for kaléo’s patient support programs.
- For patients who are unable to fill their current epinephrine prescriptions, Walgreens pharmacists will work with each patient’s healthcare practitioner to see if AUVI-Q is right for them.
Deerfield, Illinois & Richmond, Virginia (Sept. 6, 2018) – Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.
To read more click here.